Qiu Jianxin, Yu Chongxian, Ariyaratne Thathya V, Foteff Chris, Ke Zhangmin, Sun Yi, Zhang Li, Qin Feifei, Sanderson Georgina
*The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, P. R. China †Cochlear Limited Macquarie University, NSW, Australia.
Otol Neurotol. 2017 Jul;38(6):e75-e84. doi: 10.1097/MAO.0000000000001389.
To evaluate the cost utility of cochlear implantation (CI) for severe to profound sensorineural hearing loss (SNHL) among children from rural settings in P.R. China (China).
A cost-utility analysis (CUA) was undertaken using data generated from a single-center substudy of the Cochlear Pediatric Implanted Recipient Observational Study (Cochlear P-IROS). The data were projected over a 20-year time horizon using a decision tree model.
The Chinese healthcare payer and patient perspectives were adopted.
Unilateral CI of children with a severe-to-profound SNHL compared with their preimplantation state of no treatment or amplification with hearing aids ("no CI" status).
MAIN OUTCOME MEASURE/S: Incremental costs per quality adjusted life year (QALY) gained.
The mean total discounted cost of unilateral CI was CNY 252,506 (37,876 USD), compared with CNY 29,005 (4,351 USD) for the no CI status from the healthcare payer plus patient perspective. A total discounted benefit of 8.9 QALYs was estimated for CI recipients compared with 6.7 QALYs for the no CI status. From the healthcare payer plus patient perspective, incremental cost-effectiveness ratio (ICER) for unilateral CI compared with no CI was CNY 100,561 (15,084 USD) per QALY. The healthcare payer perspective yielded an ICER of CNY 40,929 (6,139 USD) per QALY. Both ICERs fell within one to three times China's gross domestic product per capita (GDP, 2011-2015), considered "cost-effective" by World Health Organization (WHO) standards.
Treatment with unilateral CI is a cost-effective hearing solution for children with severe to profound SNHL in rural China. Increased access to mainstream education and greater opportunities for employment, are potential downstream benefits of CI that may yield further societal and economic benefits. CI may be considered favorably for broader inclusion in medical insurance schemes across China.
评估在中国农村地区,人工耳蜗植入(CI)治疗重度至极重度感音神经性听力损失(SNHL)儿童的成本效用。
采用人工耳蜗植入儿童观察性研究(Cochlear P-IROS)单中心子研究产生的数据进行成本效用分析(CUA)。使用决策树模型对数据进行了20年时间跨度的预测。
采用中国医疗保健支付方和患者的视角。
重度至极重度SNHL儿童的单侧人工耳蜗植入,与植入前未治疗或使用助听器放大的状态(“未植入人工耳蜗”状态)进行比较。
每获得一个质量调整生命年(QALY)的增量成本。
从医疗保健支付方加患者的角度来看,单侧人工耳蜗植入的平均总贴现成本为252,506元人民币(37,876美元),而未植入人工耳蜗状态为29,005元人民币(4,351美元)。估计人工耳蜗植入接受者的总贴现效益为8.9个QALY,未植入人工耳蜗状态为6.7个QALY。从医疗保健支付方加患者的角度来看,单侧人工耳蜗植入与未植入人工耳蜗相比的增量成本效益比(ICER)为每QALY 100,561元人民币(15,084美元)。从医疗保健支付方的角度来看,ICER为每QALY 40,929元人民币(6,139美元)。两个ICER均落在世界卫生组织(WHO)标准认为“具有成本效益”的中国人均国内生产总值(GDP,2011 - 2015年)的一至三倍范围内。
对于中国农村地区重度至极重度SNHL儿童,单侧人工耳蜗植入治疗是一种具有成本效益的听力解决方案。增加接受主流教育的机会和更多就业机会是人工耳蜗植入潜在的下游效益,可能会带来进一步的社会和经济效益。人工耳蜗植入可被视为在中国更广泛纳入医疗保险计划的有利选择。